Corus CAD for Women
Corus CAD provides you with the only sex-specific blood test that helps you rule out the need for further evaluation for obstructive coronary artery disease (CAD)*.
Assessing CAD in Women: Diagnostic Challenges
There are many tests to help diagnose obstructive CAD, such as nuclear stress imaging, one of the most common noninvasive tests in the U.S. However, traditional tests for obstructive CAD fail to account for cardiovascular differences between men and women. As a result, women often see higher rates of false-negative and false-positive (erroneous) test results,1 leading to unnecessary downstream testing and a low diagnostic yield at invasive coronary angiography. In one study, nuclear stress imaging positively identified fewer than 50% of men and 25% of women with obstructive CAD, and the false negative rate was as high as 35% in men and 18.5% in women.2
Corus CAD: A Safe and Effective Option for Women
The Corus CAD test integrates age, sex, and the expression levels of genes as a single score with a 96% negative predictive value.3,† The higher the score, the higher the likelihood of CAD. Integrating this test result into your evaluation of clinical factors may provide you with a more complete picture of your patient's coronary artery disease status and identify patients unlikely to have obstructive CAD.
Corus CAD is the only sex-specific test for obstructive CAD that takes into consideration cardiovascular differences between men and women. Unlike other tests used by clinicians to help rule out CAD, the Corus CAD test does not involve radiation exposure or a surgical procedure. It can also be administered through a convenient peripheral blood draw. The Corus CAD test can be used along with your clinical assessment to help you rule out obstructive CAD as the cause of your non-acute patient's symptoms so you can decide on appropriate next steps.
By excluding obstructive CAD as a diagnosis, you'll be able to keep your patient from undergoing additional, often unnecessary and invasive diagnostic testing, and minimize exposure to potential risks and complications. This scenario is particularly important for female patients who may be at higher risk of side effects, such as bleeding, vascular complications, and thyroid dysfunction due to contrast agents.4,5
To order the Corus CAD test, contact your local sales representative or CardioDx Customer Service at 1.866.941.4996 or firstname.lastname@example.org.
* Obstructive CAD is defined as at least one atherosclerotic plaque causing ≥50% luminal diameter stenosis in a major coronary artery (≥1.5 mm lumen diameter) as determined by invasive quantitative coronary angiography or coronary computed tomography angiography (≥2.0 mm lumen diameter).
† The COMPASS study found that the Corus CAD algorithm has an NPV of 96% at the pre-specified threshold of 15 in the overall population of men and women referred to MPI.
- Kwok Y, Kim C, Grady D, et al. Meta-Analysis of Exercise Testing to Detect Coronary Artery Disease in Women. Am J Cardiol. 1999;83(5):660-6.
- Lansky A, Elashoff MR, Ng V, et al. A Gender-Specific Blood-Based Gene Expression Score for Assessing Obstructive Coronary Artery Disease in Nondiabetic Patients: Results of the Personalized Risk Evaluation and Diagnosis in the Coronary Tree (PREDICT) Trial. Am Heart J. 2012;164:320-326.
- Thomas GS, Voros S, McPherson JA, et al. A Blood-Based Gene Expression Test for Obstructive Coronary Artery Disease Tested in Symptomatic Nondiabetic Patients Referred for Myocardial Perfusion Imaging: The COMPASS Study. Circ Cardiovasc Genet. 2013;6(2):154-162.
- Rhee CM, Bhan I, Alexander EK, et al. Association Between Iodinated Contrast Media Exposure and Incident Hyperthyroidism and Hypothyroidism. Arch Intern Med. 2012;172:153-159.
- Ahmed B, Piper WD, Malenkat D, et al. Significantly Improved Vascular Complications Among Women Undergoing Percutaneous Coronary Intervention: A Report From the Northern New England Percutaneous Coronary Intervention Registry. Circ Cardiovasc Interv. 2009;2:423-429.